Iterative Scopes Expands its Senior Leadership Team

Iterative Scopes has welcomed two new members to its senior leadership team: Brice Wu as chief product officer (CPO), and Haig Soghigian as vice president of the newly formed Customer Success team. The pair collectively brings more than 20 years’ experience leading technical and customer service teams across a number of industries including healthcare and life sciences.
 
“We are thrilled to welcome Brice and Haig to the Iterative Scopes team,” said Richard Kho, chief operating officer at Iterative Scopes. “Their collective experience leading high-performing teams within rapidly growing SaaS companies will help strengthen our technical capabilities and accelerate both future product development and clinical site adoption of AI Recruitment.”
 
In his role as CPO, Wu is responsible for leading all product and technology development efforts across the company’s portfolio of AI-based precision medicine solutions. Previously, he served for six years as the head of Engineering and chief technology officer at Komodo Health, an enterprise SaaS healthcare technology company. During his tenure, he helped drive the company’s valuation from $55 million (Series A) to $3.3 billion (Series E). Prior to Komodo Health, Wu worked as a senior leader in data engineering, data science, and systems integration for Google’s Display Advertising and Consumer Operations organizations, overseeing more than 200 individuals operating in support of $5.2 billion in revenue and more than 90 million global users.
 
“Collectively, it’s estimated that 6-8 million people worldwide are living with the debilitating symptoms of inflammatory bowel diseases,” said Wu, “and I’m proud to be joining the talented team here at Iterative Scopes that’s using the latest in computer vision and AI technologies to truly improve patient outcomes.”
 
Wu earned his MBA from the Darden Graduate School of Business at the University of Virginia, a master’s of science degree in industrial engineering and operations research from the University of California, Berkeley, and a bachelor of science degree in materials science and engineering from Cornell University, where he was a John McMullen Dean’s Scholar.
 
As the leader of the newly-formed Customer Success team at Iterative Scopes, Soghigian oversees three functional groups responsible for ensuring a smooth onboarding experience for clinical sites enrolling in AI recruitment, providing technical support to those sites, and maintaining strong engagement with both sites and pharmaceutical partners.
 
The AI recruitment service is designed to help clinical research sites and sponsors accelerate their IBD clinical trials and more quickly and accurately identify potentially eligible IBD patients, through a combination of cutting-edge proprietary AI-driven algorithms and computer vision advances.
 
Soghigian brings a strong background in life sciences and healthcare, and has held leadership and operational management positions focused on the delivery of cloud-based services for global companies across industry verticals. Prior to joining Iterative Scopes, he worked at RapidAI, IQVIA, and Phase Forward (acquired by Oracle Health Sciences) in a number of leadership roles. Before Phase Forward, he had also spent several years at Deloitte Consulting in its technology practice.
 
“Quality of life can be significantly impacted when an individual suffers from inflammatory bowel disease,” said Soghigian. “I’m honored to be joining a company that is bringing world-class AI-solutions to patients suffering from gastrointestinal disorders.”
 
Soghigian earned his MBA from the Babson F.W. Olin Graduate School of Business, and a bachelor of science degree in entrepreneurial studies from Babson College.
 
Iterative Scopes is a pioneer in the application of artificial intelligence-based precision medicine for gastroenterology with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). The technology is also designed to potentially enhance colorectal cancer screenings. Its powerful, proprietary artificial intelligence and computer vision technologies have the potential to improve the accuracy and consistency of endoscopy readings. Iterative Scopes is initially applying these advances to impact polyp detection for colorectal cancer screenings and working to standardize disease severity characterization for inflammatory bowel disease. Spun out of MIT in 2017, the company is based in Cambridge, Mass.